

From: Wong, Greg (DPH)
Sent: Wednesday, July 9, 2025 1:31 PM
Subject: FW: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Please find below the email from the grantor. Initially, we had reached out to the grantor for an award letter from the National Institutes of Health to their organization but we were advised that they do not forward prime award information with external parties. They have forwarded an email below that confirms the award number [5UM1AI068619-19](#) which shows them as the recipient of the award from NIH, please find below. Please let me know if more information is needed. I apologize for the inconvenience.

<https://reporter.nih.gov/search/8tKqXvcg7E2Dlhwqsyq1hA/project-details/10991009>

NIH RePORT > RePORTER

Search Results > **Project Details**

[Back to Search Results](#)

HIV Prevention Trials Network Leadership and Operations Center

Description

Details

Sub-Projects

Publications

Patents

Outcomes

Clinical Studies

News and More

History

Similar Projects

Project Number
5UM1AI068619-19

Contact PI/Project Leader
COHEN, MYRON SCOTT
Other PIs

Awardee Organization
FAMILY HEALTH INTERNATIONAL

Description

Abstract Text
PROJECT SUMMARY The overarching goal of the HIV Prevention Trials Network (HPTN) is to identify acceptable, feasible, safe, effective and scalable interventions for HIV prevention that address the needs of populations at risk in the U.S. and around the world. The HPTN will address this goal by identifying: 1) new biomedical products and tools for HIV prevention that have unique characteristics, such as longer duration of action, new targets for inhibition of HIV replication, or as multipurpose prevention technologies (MPTs); and (2) integrated strategies that optimize use of proven efficacious prevention interventions and new tools tailored to specific populations at risk to achieve maximal public health impact. These interventions will be evaluated in priority populations for HIV prevention including women in sub-Saharan Africa, young men and women at risk, men who have sex with men (MSM), transgender women (TGW) who have sex with men, female sex workers (FSW) and persons who inject drugs (PWID). The specific aims of this research will be 1) To design and conduct studies of long-acting antiretroviral (ARV) agents and delivery systems for pre-exposure prophylaxis (PrEP); 2) To design and conduct studies to evaluate MPTs that concurrently prevent HIV and pregnancy, sexually transmitted infections (STIs) or opioid dependence; 3) To design and conduct studies in collaboration with the HIV Vaccine Trials Network to evaluate broadly neutralizing antibodies (bnAbs), alone and in combination, for PrEP; 4) To design and conduct integrated strategies for HIV prevention. For the first three aims, the HPTN will use a sequential multi-phase drug development strategy for the evaluation of new candidates for prevention. Phase 1 and 2 studies will be conducted for the evaluation of appropriate dose, safety and tolerability of the agent(s). The most promising systemic agents will be advanced using the criteria for a favorable target product profile for new agents including highly effective and durable protection against HIV, minimal adverse effects and drug interactions, high levels of user acceptability, and a high barrier to viral resistance. Efficacious biomedical prevention interventions will be incorporated into integrated strategy study designs that also include socio- behavioral interventions tailored to the HIV prevention imperatives and contextual needs of the specific populations at risk for HIV infection. Socio-Behavioral research (SBR) will be integral to the success of all aspects of the proposed HPTN HIV prevention agenda. Supportive SBR will be used to strengthen biomedical HIV product development (i.e. to inform user preference and ultimately product design for Phase 1-3 clinical trials), while integrative SBR will play a key role in the process of designing and adapting behavioral and structural interventions to complement biomedical interventions in integrated strategy studies. The HPTN will design and conduct the research through collaboration with its scientific leadership, its research teams, community partners, research participants, pharmaceutical companies and funders.

Sincerely,

Greg

From: Dominika Cadotte <DCadotte@fhi360.org>
Sent: Wednesday, July 9, 2025 1:20 PM
To: Wong, Greg (DPH) <greg.wong@sfdph.org>
Subject: RE: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Hi Greg,
I forgot to mention earlier, but you may be able to find some information on the public website. If you search using Award #5UM1AI068619-19, you should be able to confirm that FHI 360 is listed as a recipient of the award.

We all work flexibly and across time zones. I am sending this message at a time that works well for me; please reply at a time that works well for you.

Dominika Cadotte
Contracts and Grants Officer



1825 Connecticut Ave NW
Washington, DC, 20009
dcadotte@fhi360.org
P 1.202.884.8199



fhi360.org | [FHI 360 Facebook](#) | [FHI 360 Twitter](#)

From: Dominika Cadotte <DCadotte@fhi360.org>
Sent: Wednesday, July 9, 2025 1:02 PM
To: Wong, Greg (DPH) <greg.wong@sfdph.org>; Sarah Azimi <SAzimi@fhi360.org>; Gloria Pherribo <GPherribo@fhi360.org>
Cc: Beth Farrell <BFarrell@fhi360.org>; Chiong, Christina (DPH) <Christina.Chiong@sfdph.org>
Subject: RE: For Signature HPTN 113 PO24002400 SFDPH City and County SF - Modification #1

Dear Greg,

Thank you for your email and for raising this question.

Please note that FHI 360 does not share award documentation established between our organization and the funder with external parties. We appreciate your understanding on this matter.

That said, we do have a direct agreement in place with SFDPH. This agreement defines SFDPH and FHI 360 relationship and obligations. If there are any concerns or questions related to that agreement, please don't hesitate to raise them, we would be happy to address them.

Best regards,

We all work flexibly and across time zones. I am sending this message at a time that works well for me; please reply at a time that works well for you.

Dominika Cadotte
Contracts and Grants Officer



1825 Connecticut Ave NW
Washington, DC, 20009
dcadotte@fhi360.org
P 1.202.884.8199



fhi360.org | [FHI 360 Facebook](#) | [FHI 360 Twitter](#)